Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2009 - 2021)
Vertex Pharmaceuticals (VRTX) posted quarterly Long-Term Debt Issuances of $10.0 million for Q4 2021, up 114.68% year-over-year from $4.7 million in Q4 2020, and up 900.0% quarter-over-quarter from $1.0 million in Q3 2021.
Vertex Pharmaceuticals (VRTX) Long-Term Debt Issuances (2009 - 2021) Analysis & Trends
Vertex Pharmaceuticals' Long-Term Debt Issuances history runs 10 years deep, the most recent figure standing at $10.0 million for Q4 2021.
- In Q4 2021, Long-Term Debt Issuances rose 114.68% year-over-year to $10.0 million; the TTM figure through Sep 2022 stood at $10.0 million (down 42.06% YoY), while the FY2021 annual figure was $22.6 million, up 69.92% from the prior year.
- Long-Term Debt Issuances for Q4 2021 stood at $10.0 million, up from $1.0 million in the prior quarter.
- The five-year high for Long-Term Debt Issuances was $30.0 million in Q4 2017, with the low at $1.0 million in Q3 2021.
- The 5-year median for Long-Term Debt Issuances is $5.3 million (2017), against an average of $7.2 million.
- The sharpest annual moves came in 2017 and 2018: Long-Term Debt Issuances surged 1576.16% in 2017, then plunged 73.78% in 2018.
- Vertex Pharmaceuticals' Long-Term Debt Issuances stood at $30.0 million in 2017, then slumped by 73.78% to $7.9 million in 2018, then grew by 14.52% to $9.0 million in 2019, then tumbled by 48.23% to $4.7 million in 2020, then soared by 114.68% to $10.0 million in 2021.
- Business Quant data shows VRTX's Long-Term Debt Issuances at $10.0 million in Q4 2021, $1.0 million in Q3 2021, and $8.0 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -675,522.58 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 1.00 Mn |
| Sep 30, 2021 | 1.00 Mn |
| Jun 30, 2021 | 8.00 Mn |
| Jun 30, 2021 | 8.00 Mn |
| Mar 31, 2021 | 3.60 Mn |
| Mar 31, 2021 | 3.60 Mn |
| Dec 31, 2020 | 4.66 Mn |
| Dec 31, 2020 | 4.66 Mn |
| Sep 30, 2020 | 2.81 Mn |
| Sep 30, 2020 | 2.81 Mn |
| Mar 31, 2020 | 5.83 Mn |
| Mar 31, 2020 | 5.83 Mn |
| Dec 31, 2019 | 9.00 Mn |
| Dec 31, 2019 | 9.00 Mn |
| Jun 30, 2019 | 1.00 Mn |
| Jun 30, 2019 | 1.00 Mn |
| Dec 31, 2018 | 7.86 Mn |
| Dec 31, 2018 | 7.86 Mn |